ClinicalTrials.gov
public full text
Public Domain
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anti-Inflammatory Treatment of Schizophrenia#854626
- Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate#1150126
- Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis#1057778
- Phase 2 Trial of a Nicotinic Agonist in Schizophrenia#1309259
- Minocycline for the Treatment of Early-Phase Schizophrenia#1046902
Record · ID 1186146
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive